Metraipolis › archive › dc_818a423fb663

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens — Europe PMC PMID:34679128

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34679128
DOI
10.1371/journal.ppat.1009807
License (as archived)
CC0-1.0
Archived
2026-11-02T06:51:19.830Z
SHA-256 of the archived text
a8d574c6960eb1a7989ce5fba4868776e517ce147a872aeacc04348141457065
Stable URL of this page
https://metraipolis.com/documento/dc_818a423fb663

How to cite

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens — Europe PMC PMID:34679128 — Europe PMC (en), https://europepmc.org/article/MED/34679128 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_818a423fb663 (Metraipolis archive dc_818a423fb663, sha256 a8d574c6960eb1a7989ce5fba4868776e517ce147a872aeacc04348141457065)
BibTeX
@misc{dc818a423fb663,
  title = {Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens — Europe PMC PMID:34679128},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34679128},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_818a423fb663; sha256 a8d574c6960eb1a7989ce5fba4868776e517ce147a872aeacc04348141457065},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34679128. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

HIV-1 vaccine immunofocusing strategies may be able to induce broadly-reactive neutralizing antibodies (NAbs). Here, we engineered a panel of diverse, membrane-resident native HIV-1 trimers vulnerable to two broad targets-the V2 apex and fusion peptide (FP). Selection criteria included i) high expression and ii) infectious function, so that trimer neutralization sensitivity can be profiled in pseudovirus (PV) assays. Initially, we boosted the expression of 17 candidate trimers by truncating gp41 and introducing a gp120-gp41 SOS disulfide to prevent gp120 shedding. "Repairs" were made to fill glycan holes and eliminate other strain-specific aberrations. A new neutralization assay allowed PV infection when our standard assay was insufficient. Trimers with exposed V3 loops, a target of non-NAbs, were discarded. To try to increase V2-sensitivity, we removed clashing glycans and modified the C-strand. Notably, a D167N mutation improved V2-sensitivity in several cases. Glycopeptide analysis of JR-FL trimers revealed near complete sequon occupation and that filling the N197 glycan hole was well-tolerated. In contrast, sequon optimization and inserting/removing glycans at other positions frequently had global "ripple" effects on glycan maturation and sequon occupation throughout the gp120 outer domain and gp41. V2 MAb CH01 selectively bound to trimers with small high mannose glycans near the base of the V1 loop, thereby avoiding clashes. Knocking in a rare N49 glycan was found to perturb gp41 glycans, increasing FP NAb sensitivity-and sometimes improving expression. Finally, a biophysical analysis of VLPs revealed that i) ~25% of particles bear Env spikes, ii) spontaneous particle budding is high and only increases 4-fold upon Gag transfection, and iii) Env+ particles express ~30-40 spikes. Taken together, we identified 7 diverse trimers with a range of sensitivities to two targets to allow rigorous testing of immunofocusing vaccine concepts.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2021 (prima pubblicazione 2021-10-22).
Identificativi: PMID 34679128 · PMCID PMC8565784 · DOI 10.1371/journal.ppat.1009807.
Pagina: https://europepmc.org/article/MED/34679128 — https://doi.org/10.1371/journal.ppat.1009807. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-02T06:42:43.100Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.